Insights from Dr Andrew Pink
The treatment landscape for atopic dermatitis (AD) has expanded rapidly with the development of targeted biologic therapies that address specific pathways within the type-2 inflammatory cascade.
Among these emerging treatments, nemolizumab represents a novel approach by targeting a pathway closely linked to itch, the symptom that many patients find most debilitating.
In this expert interview series, Dr Andrew Pink, consultant dermatologist and the director of the adult Clinical Trials Unit at St. John’s Institute of Dermatology, Guy’s and St Thomas’ Hospitals, London, shares clinical perspectives on the role of nemolizumab in AD management. He discusses its rapid impact on itch, improvements in sleep, treatment timelines, and considerations when selecting therapy for patients with different disease profiles.
Rapid Relief of Itch
One of the most meaningful treatment outcomes for patients with atopic dermatitis is the speed at which itch improves.
Persistent pruritus can significantly disrupt sleep, daily functioning, and emotional wellbeing. As such, treatments that provide rapid itch relief may have an immediate impact on a patient’s quality of life.
Dr Pink notes that some targeted therapies demonstrate very rapid reductions in itch, with clinical trial observations suggesting that improvements may occur within the first few days of treatment. This contrasts with other biologic therapies targeting type-2 inflammation, which, while effective, may take several weeks before patients experience significant symptom relief.
Improvements in Skin Lesions Over Time
While itch reduction may occur quickly with certain targeted therapies, improvements in visible skin inflammation may follow a different timeline.
Dr Pink explains that objective disease measures often improve progressively over time, even after early symptom relief has been achieved. Patients may notice gradual improvements in skin lesions over several months, with maximal disease control sometimes observed after prolonged treatment.
This gradual trajectory is important for clinicians to communicate during treatment initiation. When patients experience early improvements in itch alongside steady progress in skin clearance, overall satisfaction with treatment tends to remain high.
The Impact of Itch Control on Sleep
Sleep disturbance is one of the most common consequences of chronic itch in atopic dermatitis.
Clinical trial data consistently shows that sleep quality improves alongside reductions in itch severity. As itch diminishes, patients experience fewer nighttime awakenings and better overall sleep quality.
Dr Pink highlights that sleep improvements often follow the same trajectory as itch reduction. When treatments rapidly reduce pruritus, improvements in sleep may occur just as quickly.
Selecting the Right Therapy for the Right Patient
Choosing an appropriate therapy for atopic dermatitis requires careful consideration of several patient-specific factors.
Patients with AD are highly heterogeneous, and clinicians must evaluate multiple elements when selecting treatment, including:
- age
- disease severity
- comorbidities
- symptom profile
- treatment preferences
Certain targeted therapies may be particularly beneficial for patients with severe itch, where rapid symptom control is a priority. Safety profiles, dosing schedules, and potential effects on comorbid conditions may also influence treatment choice.
Dr Pink notes that therapies targeting different immune pathways may offer distinct advantages depending on the patient’s phenotype and clinical needs.
The Importance of Treatment Persistence
Atopic dermatitis is a chronic inflammatory disease, and long-term treatment strategies are often required to maintain disease control.
Dr Pink emphasises that clinicians should carefully evaluate treatment response over time. Even when complete disease clearance is not achieved immediately, continued improvement may occur with sustained therapy.
In some cases, adjunctive treatments may be introduced if progress plateaus after an initial improvement. Setting realistic expectations with patients regarding the timeline of response is therefore an essential part of clinical management.
Treating Patients with Overlapping Conditions
Some patients present with both atopic dermatitis and prurigo nodularis (PN), two conditions that share overlapping itch pathways.
Dr Pink notes that certain targeted therapies may provide benefits in patients with both conditions due to shared underlying mechanisms. However, the number of treatments supported by strong clinical evidence for both diseases remains limited.
For these patients, selecting a therapy with evidence across both disease states may help address the complex symptom burden associated with chronic itch.
This article is part of a three-part expert series featuring insights from Dr Andrew Pink on the evolving understanding and management of atopic dermatitis.
Explore the other articles:
